

The Drug Utilization Review Board Reviewed the Following New Drugs and Classes on June 21, 2012

The Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drugs and classes for the Georgia Medicaid FFS Preferred Drug List (PDL).

New Drug Reviews

Antihemophilic Agent

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Corifact*^{TM}.

Chelating Agent

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Ferriprox*^{TM}.

<u>Antineoplastic</u>

The DUR Board recommended *Preferred* status for *Jakafi*TM.

Agent for Gaucher Disease

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Vpriv*^{\mathbb{M}}.

Class Reviews

Only the classes that include a drug with a recommendation for change in PDL status are highlighted below. The recommendations on all other classes and the drugs within those classes remained the same as the current PDL status, which is located at http://dch.georgia.gov/pharmacy under the Preferred Drug Lists link or directly at http://dch.georgia.gov/00/channel_title/0,2094,31446711_32050640,00.html.

Protease Inhibitors for Hepatitis C

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Incivek*[®] and *Victrelis*[®].

Agents for Hereditary Angioedema

The DUR Board recommended *Preferred* status for *Berinert[®]*, *Cinryze[®]* and *Firazyr[®]* and *Non-Preferred* status for *Kalbitor[®]*.

Atypical Antipsychotics

The DUR Board recommended *Preferred* status for *Equetro*[®]; *Preferred* status with *Prior Authorization* for ages less than FDA-approved for all generics, *olanzapine, quetiapine, risperidone* and *ziprasidone*; *Preferred* status with *Prior Authorization* for ages less than FDA-approved and trial of one generic for *Abilify*[®] and *Latuda*[®]; and *Non-Preferred* status with *Prior Authorization* for all other atypical antipsychotics.